The purpose of this paper is to examine whether alliance portfolio R&D intensity contributes to biopharmaceutical firms' number of new product approvals and whether alliance portfolio R&D intensity is more positively related to the number of new product approvals for pharmaceutical firms than for biotechnology firms.
The paper employs a random effects Poisson regression model using panel data of 821 firm year observations for 146 biopharmaceutical firms operating in the USA. The robustness of results is also checked with additional analysis, provided in an appendix.
The results of this study show that the R&D intensity of firms' alliance portfolios is positively related to their new product introductions. It is also found that alliance portfolio R&D intensity has a more positive impact on the pharmaceutical segment of the industry's new product introductions than those of the biotechnology segment.
The authors develop and test theory about how the combined effects of two dimensions of alliance portfolio configuration (size and relationship strength) positively impact new product development. The authors propose a two dimensional alliance portfolio configuration measure, alliance portfolio R&D intensity. They combine the number of R&D alliances relative to the total number of alliances in the portfolio with the differential strength of ties associated with resource commitments required to source information from upstream and downstream alliances.
